Literature DB >> 24411279

A feasible and time-efficient adaptation of NeuroSAFE for da Vinci robot-assisted radical prostatectomy.

Burkhard Beyer1, Thorsten Schlomm1, Pierre Tennstedt1, Katharina Boehm1, Meike Adam1, Jonas Schiffmann1, Guido Sauter2, Corina Wittmer2, Thomas Steuber1, Markus Graefen1, Hartwig Huland1, Alexander Haese3.   

Abstract

BACKGROUND: The benefit of intraoperative neurovascular structure-adjacent frozen section examination (NeuroSAFE) of the prostate was demonstrated in open radical prostatectomy. In da Vinci robot-assisted prostatectomy (DVP), this approach is often avoided due to suspected difficulties in harvesting the prostate, loss in pneumoperitoneum, increased blood loss, and prolonged operating room (OR) time.
OBJECTIVE: To provide a detailed description of the technique, feasibility, and impact of the NeuroSAFE technique on OR time, blood loss, frequency of nerve sparing (NS), and positive surgical margins (PSMs) in DVP. DESIGN, SETTING, AND PARTICIPANTS: We analyzed 1570 consecutive patients undergoing DVP from 2004 to 2012. NeuroSAFE was performed in 1178 patients. SURGICAL PROCEDURE: The prostate was intraoperatively harvested via an extension of the camera trocar incision without undocking the robotic arms. Blood spillage from the dorsal vein complex due to the loss of pneumoperitoneum was avoided by upward traction on the transurethral catheter. After prostate removal, pneumoperitoneum was reestablished by closing the extended incision with running sutures and repositioning the optical trocar. The NeuroSAFE procedure consisted of intraoperative bilateral frozen sections covering the entire neurovascular bundles adjacent prostate surface. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We compared OR time, blood loss, NS frequency, and PSMs in non-NeuroSAFE versus NeuroSAFE DVP. RESULTS AND LIMITATIONS: There was no significant difference in blood loss (253.5 ± 204.4 ml vs 265.8 ± 246.7 ml; p=0.49) and OR time (220 min ± 51 vs 224 min ± 64; p=0.22). No complications associated with specimen harvesting occurred. NS rate increased significantly with versus without NeuroSAFE (overall 97% vs 81%; pT2 99% vs 90%, pT3a 94% vs 74%, pT3b 91% vs 30). PSM rate dropped significantly with NeuroSAFE (overall 16% vs 24%; pT2 8% vs 15%, pT3a 22% vs 39%, pT3b 49% vs 67%; all p<0.05).
CONCLUSIONS: We demonstrate a time-efficient and safe adaption of the NeuroSAFE technique to DVP. PATIENT
SUMMARY: We describe a feasible and secure adaption of the neurovascular structure-adjacent frozen section examination (NeuroSAFE) procedure for da Vinci robot-assisted prostatectomy. We showed that there was no increased blood loss and operating room time. We maximized the nerve-sparing frequency and could reduce positive surgical margins even in non-organ-confined tumors.
Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Frozen section analysis; Nerve sparing; NeuroSAFE; Robotic prostatectomy

Mesh:

Year:  2013        PMID: 24411279     DOI: 10.1016/j.eururo.2013.12.014

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  21 in total

1.  Prognostic value of unifocal and multifocal positive surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer.

Authors:  Etienne Xavier Keller; Jacqueline Bachofner; Anna Jelena Britschgi; Karim Saba; Ashkan Mortezavi; Basil Kaufmann; Christian D Fankhauser; Peter Wild; Tullio Sulser; Thomas Hermanns; Daniel Eberli; Cédric Poyet
Journal:  World J Urol       Date:  2018-12-05       Impact factor: 4.226

2.  Intraoperative Frozen Section of the Prostate Reduces the Risk of Positive Margin Whilst Ensuring Nerve Sparing in Patients with Intermediate and High-Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy: First Reported UK Series.

Authors:  Nikhil Vasdev; Samita Agarwal; Bhavan P Rai; Arany Soosainathan; Gregory Shaw; Sebastian Chang; Venkat Prasad; Gowrie Mohan-S; James M Adshead
Journal:  Curr Urol       Date:  2016-05-20

3.  No impact of blood transfusion on oncological outcome after radical prostatectomy in patients with prostate cancer.

Authors:  K Boehm; B Beyer; P Tennstedt; J Schiffmann; L Budaeus; A Haese; M Graefen; T Schlomm; H Heinzer; G Salomon
Journal:  World J Urol       Date:  2014-07-03       Impact factor: 4.226

4.  Prostate cancer: Nerve-sparing surgery and risk of positive surgical margins.

Authors:  Katharina Boehm; Markus Graefen
Journal:  Nat Rev Urol       Date:  2015-01-06       Impact factor: 14.432

5.  Re: What is the role of NeuroSAFE in robotic radical prostatectomy?

Authors:  Eoin Dinneen; A Haider; J Grierson; T Briggs; R Persad; N Oakley; A Freeman; G Shaw
Journal:  J Robot Surg       Date:  2019-04-12

6.  Impact of surgeon-defined capsular incision during radical prostatectomy on biochemical recurrence rates.

Authors:  Philipp Mandel; Su J Oh; Christoph Hagner; Pierre Tennstedt; Maximilian C Kriegmair; Hartwig Huland; Markus Graefen; Derya Tilki
Journal:  World J Urol       Date:  2016-03-22       Impact factor: 4.226

Review 7.  [Radical prostatectomy in locally advanced prostate cancer].

Authors:  P Mandel; D Tilki; M Graefen
Journal:  Urologe A       Date:  2017-11       Impact factor: 0.639

8.  What is the role of Neurosafe in robotic radical prostatectomy?

Authors:  S S Goonewardene; D Cahill
Journal:  J Robot Surg       Date:  2018-05-10

9.  Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time.

Authors:  Geoffrey A Sonn; Andrew S Behesnilian; Ziyue Karen Jiang; Kirstin A Zettlitz; Eric J Lepin; Laurent A Bentolila; Scott M Knowles; Daniel Lawrence; Anna M Wu; Robert E Reiter
Journal:  Clin Cancer Res       Date:  2015-10-21       Impact factor: 12.531

10.  [Systematic analysis of treatment results as a quality control instrument using the example of a large European center].

Authors:  B Beyer; H Huland; M Graefen
Journal:  Urologe A       Date:  2015-11       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.